重组人促血小板生成素治疗急性白血病化疗后血小板减少症的疗效

Recombinant human thrombopoietin in treatment of chemotherapy induced thrombocytopenia in patients with acute leukemia

目的总结急性白血病化疗后血小板减少症的治疗经验。方法将52例急性白血病化疗后血小板减少症患者随机分为治疗组(n=26)和对照组(n=26),治疗组使用重组人促血小板生成素(rhTPO)治疗,对照组使用重组人白介素11(rhIL-11)治疗,比较2组出血表现、血小板变化情况、输血依赖情况及不良反应。结果治疗组出血患者例数低于对照组(P<0.05)。治疗组血小板恢复时间平均为(7.35±2.64)d,对照组为(9.73±1.89)d,治疗组明显低于对照组(P<0.05);化疗后治疗组平均每位患者输血依赖频率为(2.73±0.43),对照组为(4.21±0.60),治疗组输液依赖频率明显低于对照组(P<0.05);与对照组比较,治疗组rhTPO相关不良反应发生率明显低于对照组rhIL-11相关的不良反应发生率(P<0.05)。结论rhTPO是治疗急性白血病化疗后血小板减少症的有效方法。

Objective To summarize the experiences of the treatment of chemotherapy-in- duced thrombocytopenia in patients with acute leukemia. Methods Fifty-two patients with acute leukemiawho who had thrombocytopenia after chemotherapy were randomly divided into treatment and control groups. The treatment group received hyrepodermic injection with combinant human thrombopoietin, while the control group received recombinant human interleukin-ll. The bleeding representations, the changes of platelet count, the times of platelet transfusion and the side effects were compared in the two groups during the course of treatment. Results There were less patients who bled in the treatment group during the course than in the control group （P 〈 0.05）. The time of declined platelet count increasing to the normal count was （7.35 ±2.64） days in the treatment group which was significantly shorter than （9.73 ±1.89） days in the control group （P 〈 0.05）. The average times of platelet transfusion in the treatment group was （2.73 ±0.43）after chemical therapy while in the control group was（4.21 ± 0.60）. The frequency rate of the treatment group was significantly lower than the control group （P 〈 0.05）. Compared to the control group, the fre- quency of rhTPO-related adverse events in the treatment group was much lower than the frequency of RHIL-11 related adverse （P 〈 0.05）. Conclusion rhTPO is effective and safe for chemotherapy -induced thrombocytopenia in patients with acute leukemia.